Eli Lilly's first antibody-based drug for COVID-19 has been granted emergency approval by the US FDA.
According to Ukrinform, AR reports this.
FDA approves experimental drug Bamlanivimab for treatment of patients 12 years and older with mild to moderate COVID-19 who do not require hospitalization. The drug is injected into the patient's body through a dropper once.
Early test results suggest Bamlanivimab can help clear the virus faster and possibly reduce the likelihood of hospitalization in people with mild to moderate COVID-19.
It is noted that the therapy is now undergoing additional testing to establish its safety and effectiveness..
At the same time, it is noted that only one drug - Remdesivir from Gilead Sciences - has full FDA approval for the treatment of COVID-19. Government guidelines for the treatment of this disease also include Dexamethasone and other steroids for some critically ill hospitalized patients..